{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:04:42Z","timestamp":1790337882507,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["409525714"],"award-info":[{"award-number":["409525714"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational All"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tralokinumab, an interleukin\u201013 (IL\u201013) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate\u2010to\u2010severe atopic dermatitis (AD). This study aims to evaluate clinical and immunological outcome upon tralokinumab treatment in a real\u2010world cohort of patients with moderate\u2010to\u2010severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We recruited 81 AD patients receiving tralokinumab, performing clinical assessments (oScorad, IGA, BSA, DLQI, pruritus\u2010VAS) at baseline and months 3, 6, 9, and 12. For immunophenotyping (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a025), PBMCs were collected at baseline and months 6\/12. Peripheral T\u2010cell subsets, CLA, OX40, TFH, and cytokines (IL\u20104, IL\u201013, IL\u201017A, IL\u201010, IFN\u03b3) were analyzed via multiparametric flow cytometry. Serum total\/specific IgEs were measured by ImmunoCap and eosinophils by differential blood counts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Tralokinumab treatment induced a continued clinical response: at 12\u00a0months, oScorad and BSA decreased by 60.8% and 78.8%. CLA\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells declined by 63.0% and 25.8%, and OX40\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells by 62.4% and 44.0%. CD4\n                      <jats:sup>+<\/jats:sup>\n                      effector memory T cells increased 4.6\u2010fold, while TEMRA cells decreased 34.0%. CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells expressing IL\u201013, IL\u20104, and IL\u201017A declined by 70.8%, 72.8%, and 69.3%, while IFN\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      and IL\u201010\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells increased by 62.0%. Total IgE decreased by 9.7%, while eosinophil counts remained stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real\u2010world practice, tralokinumab achieves robust clinical benefit and a rebalanced systemic immune pattern. Selective IL\u201013 blockade reshapes T\u2010cell function, shifting the immune balance from Th2\/Th17 dominance toward Th1\/regulatory profiles, suggesting immunomodulatory effects consistent with disease modification. Future studies are needed to determine the long\u2010term stability of these immunological changes following treatment prolongation or interruption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/clt2.70200","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:20:10Z","timestamp":1788754810000},"source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5664-1970","authenticated-orcid":false,"given":"Meslina","family":"Almaci","sequence":"first","affiliation":[{"name":"Division of Allergy and Immunology Department of Dermatology, Venerology and Allergy Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0681-4553","authenticated-orcid":false,"given":"Philipp","family":"Globig","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology Department of Dermatology, Venerology and Allergy Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-0844","authenticated-orcid":false,"given":"Davender","family":"Redhu","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology Department of Dermatology, Venerology and Allergy Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-1245","authenticated-orcid":false,"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology Department of Dermatology, Venerology and Allergy Charit\u00e9 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010018\u20100001\u2010z"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943640"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398\u20109995.2005.00733.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13120"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100214"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16414"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001341\u20101"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.296"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19382"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247298"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.005"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70062"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010024\u201001143\u2010x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16108"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010020\u201000577\u20101"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.S474411"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.019"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2554"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.053"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16121"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14228"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u2010065X.2009.00766.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.v29.i3.10"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0058"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010023\u201000838\u20109"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445163"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad498.026"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103452"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.022"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.31.606077"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.03.1659"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.037"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010immunol\u2010090222\u2010102834"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13596"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.008"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2020.1776079"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2024.4750"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18753"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100519"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/WOX.0b013e3181661472"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clt2.70200","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:43:06Z","timestamp":1790336586000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/clt2.70200"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70200","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"e70200"}}